- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02926170
Rivaroxaban for Patients With Antiphospholipid Syndrome
May 4, 2018 updated by: Hospital Universitari Vall d'Hebron Research Institute
Rivaroxaban Versus Acenocumarol for Secondary Thromboprophylaxis in Patients With Antiphospholipid Syndrome: a Randomized, Prospective, Phase III Study. Analysis of Stratification Prognostic Factors
Long-term anticoagulation is widely used for secondary thromboprophylaxis in the antiphospholipid syndrome (APS) due to the high risk of recurrent events.
Currently anticoagulation with vitamin K antagonists (VKAs) is the standard of care but have unpredictable pharmacodynamic properties that requiere monitoring for dose adjustment.
Rivaroxaban, an orally active direct factor Xa inhibitor, has been shown to be effective and safe compared with warfarin for the treatment of venous thromboembolism and non valvular atrial fibrillation in major RCTs.
No studies had been published in APS.The aim of the study is to investigate the efficacy and safety of rivaroxaban in preventing recurrent thrombosis in patients with APS compared with acenocoumarol
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a phase 3 randomized, multicenter, non-inferiority open-label RCT.
190 eligible APS patients with arterial or venous thrombotic history receiving acenocoumarol will be stratified according the presence of SLE and venous/arterial thrombotic history and randomized (1:1) either to continue vitamin K antagonists (standard of care, normalized ratio (INR) 2-3 or 2.5 to 3.5 in those with recurrent thrombotic episodes) or to switch to rivaroxaban (20 mg/day).
The primary efficacy outcome is the development of any thrombotic event during the study period.
Secondary efficacy outcomes include time to thrombosis, type of thrombosis (arterial or venous), overall causes of death, evaluation of a prognostic biomarker panel of recurrent thrombosis.
The primary safety outcome will be major bleeding.
Secondary safety outcomes include any adverse event and minor bleeding.
Study Type
Interventional
Enrollment (Actual)
190
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Barcelona, Spain, 08035
- Vall D'Hebron University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with thrombotic antiphsopholipd syndrome
- Treated with acenocumarol for a minimum period of 6 months
- Positivity for Lupus anticoagulant and/or anti-cardiolipin or anti-B2GPI antibodies IgG or IgM≥40
Exclusion Criteria:
- Major haemorrhage (cerebral or gastrointestinal) within the previous 6 months
- Neurosurgery within the previous 4 weeks
- Any surgery within the previous 10 days
- Active peptic ulcus
- ALT or GPT >120 UI/mL non-lupus related in the previous 30 days
- Platelets <30x10E9 in the previous 30 days
- Recent diagnosed malignancy
- Any criteria listed in the summary of the produt characterisitcs (SPC)
- Renal disease with a creatinine clearance <30 mL/min or with a known uncontrolled renal disease
- Concomitant administration of drugs that could interfere with CYP3A4
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: rivaroxaban
Rivaroxaban 20 mg per day
|
Rivaroxaban will be started at 20 mg/day.
Dose will be adjusted according to Cr Clearance.
Cr Clearance 30-49 ml/min will receive 15 mg/day.
Other Names:
|
Active Comparator: acenocumarol
INR adjusted dose
|
Doses will be adjusted according to INR
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Developement of a new thrombotic event (arterial or venous), confirmed by appropiate imaging studies
Time Frame: 36 months
|
Stroke or transient ischemic attack, myocardial infarction, peripheral arterial thrombosis, cerebral vein thrombosis, deep-vein thrombosis, or pulmonary embolism) that was confirmed by adjudication
|
36 months
|
Incidence of major bleeding
Time Frame: 36 months
|
Major bleeding is defined as clinically overt bleeding associated with any of the following: fatal bleeding causing death, involvement of a critical anatomic site (intracranial, spinal, intraocular, pericardial, articular, retroperitoneal, or intramuscular with compartment syndrome) or need for surgery or angiographic intervention to stop haemorrhage, fall in haemoglobin concentration of at least 20 g/L in 24 hours, and/or requiring non-planned transfusion of ≥2 units of packed red blood cells or whole blood
|
36 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of any treatment-Emergent Adverse events
Time Frame: 36 months
|
i) all adverse events; ii) serious adverse events (SAE); iii) all bleeding events; iv) overall causes of death
|
36 months
|
Death due to thrombotic events
Time Frame: 36 months
|
Death as result of a thrombotic event
|
36 months
|
Time to the first thrombotic event
Time Frame: 36 months
|
Time (months) from the treatment onset up to the thrombotic event
|
36 months
|
Location of thrombotic events
Time Frame: 36 months
|
Location (arterial or venous) whenre the thrombotic event occurred
|
36 months
|
Evaluation of a prognostic biomarker panel
Time Frame: 36 months
|
Measuremnt of D-dimer, P-selectine and Von-willebrand factor
|
36 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Josefina Cortes, MD,pHD, Vall d'Hebron Research Institute
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 13, 2013
Primary Completion (Actual)
December 31, 2017
Study Completion (Actual)
December 31, 2017
Study Registration Dates
First Submitted
October 3, 2016
First Submitted That Met QC Criteria
October 5, 2016
First Posted (Estimate)
October 6, 2016
Study Record Updates
Last Update Posted (Actual)
May 11, 2018
Last Update Submitted That Met QC Criteria
May 4, 2018
Last Verified
May 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2010-019764-36
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Antiphospholipid Syndrome
-
Cairo UniversityCompletedPrimary Antiphospholipid SyndromeEgypt
-
University of FloridaHoffmann-La RocheCompletedAntiphospholipid Antibody SyndromeUnited States
-
Hospital Universitario Pedro ErnestoCompletedAntiphospholipid Antibody Syndrome
-
Italian Society for RheumatologyRecruitingAntiphospholipid Syndrome | Seronegative Antiphospholipid SyndromeItaly
-
Duke UniversityRecruitingAntiphospholipid SyndromeUnited States
-
Yale UniversityNational Institute of Allergy and Infectious Diseases (NIAID); Hospital for...Active, not recruitingAntiphospholipid Syndrome (APS)United States
-
Richard Burt, MDWithdrawnANTIPHOSPHOLIPID SYNDROMEUnited States
-
Ruijin HospitalRecruitingAntiphospholipid Syndrome (APS)China
-
University Hospital, RouenUnknownAntiphospholipid Syndrome (APS)France
-
University Hospital, AngersUnknownPrimary Antiphospholipid SyndromeFrance
Clinical Trials on Rivaroxaban
-
Portola PharmaceuticalsCompleted
-
Korea University Anam HospitalRecruitingAtrial Fibrillation | Anticoagulant Adverse ReactionKorea, Republic of
-
Doasense GmbHActive, not recruitingAnticoagulant TherapyGermany
-
China National Center for Cardiovascular DiseasesNot yet recruitingStroke | Atrial Fibrillation | Major Adverse Cardiac Events | Anticoagulant Adverse Reaction
-
BayerCompleted
-
The Affiliated Hospital of Qingdao UniversityCompletedHealthy SubjectsChina
-
BayerJanssen R&D, L.L.C.Completed
-
BayerJanssen Research & Development, LLCCompletedCoronary Artery Disease | Cardiovascular DiseaseBelgium, Netherlands
-
University Hospital, GrenobleCompleted
-
Addpharma Inc.CompletedEmbolism and ThrombosisKorea, Republic of